IP Library Granted Patent US 8,840,906
Granted Patent B2
US 8,840,906 · App. 12/675,597 · Granted Sep 23, 2014

Methods and compositions related to immunizing against

Inventors: Juliane Bubeck-Wardenburg (Frankfort, IL); Olaf Schneewind (Chicago, IL); Brook Ragle (Chicago, IL)
Assignee: The University of Chicago
A61K39/085A61K2039/505C07K16/1271C07K2316/96
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,840,906
App. No.
12/675,597
Granted
Sep 23, 2014
Kind
B2
Abstract

Embodiments of the invention include methods and compositions useful in a vaccination strategy capable of neutralizing HIa to provide immunoprotection against S. aureus pneumonia. In certain aspects the invention includes a HIa with reduced toxicity, represented by a recombinant mutant form of HIa (HlaH35L) in which histidine 35 is converted to leucine, which can be used to abrogate the productive assembly of the toxin and protect a subject from staphylococcal pneumonia.

Claims (23)

1. A method of eliciting an immune response in a patient to a staphylococcal bacteria, wherein the patient is hospitalized or will be hospitalized or the patient will undergo surgery and/or be anesthetized, comprising administering to a patient an effective amount of a composition comprising a purified recombinant and attenuated Staphylococcus α-hemolysin (Hla) toxin, wherein the composition contains no more than contaminating amounts of any other Staphylococcus protein.

2. The method of claim 1 , wherein the attenuated Hla toxin lacks detectable hemolytic activity and/or the attenuated Hla toxin lacks detectable lethal activity.

3. The method of claim 1 , wherein the Hla toxin has a leucine substituted for a histidine at amino acid 35.

4. The method of claim 1 , wherein the Hla toxin is not substantially denatured.

5. The method of claim 1 , further comprising testing the patient for antibodies against Hla toxin.

6. The method of claim 1 , wherein the patient is administered the composition multiple times.

7. The method of claim 1 , wherein the composition further comprises at least one adjuvant.

8. The method of claim 7 , wherein the adjuvant is conjugated to the Hla toxin.

9. The method of claim 1 , wherein the composition is administered mucosally, intramuscularly, intranasally, or is inhaled.

10. The method of claim 1 , wherein the patient has a staphylococcal lung disease or condition.

11. A method of eliciting an immune response in a patient to a staphylococcal bacteria, wherein the patient is hospitalized or will be hospitalized; or the patient will undergo surgery and/or be anesthetized, comprising administering to a patient an effective amount of a composition comprising a purified recombinant and attenuated Staphylococcus α-hemolysin (Hla) toxin, wherein the composition further comprises at least one adjuvant conjugated to Hla, and wherein the composition contains no more than contaminating amounts of any other Staphylococcus protein.

12. The method of claim 11 , wherein the attenuated Hla toxin lacks detectable hemolytic activity and/or the attenuated Hla toxin lacks detectable lethal activity.

13. The method of claim 11 , wherein the Hla toxin has a leucine substituted for a histidine at amino acid 35.

14. The method of claim 11 , wherein the Hla toxin is not substantially denatured.

15. The method of claim 11 , further comprising testing the patient for antibodies against Hla toxin.

16. The method of claim 11 , wherein the patient is administered the composition multiple times.

17. The method of claim 11 , wherein the composition is administered mucosally, intramuscularly, intranasally, or is inhaled.

18. The method of claim 11 , wherein the patient has a staphylococcal lung disease or condition.

19. The method of claim 18 , wherein the staphylococcal lung disease or condition is pneumonia.

20. A method of eliciting an immune response in a patient to a staphylococcal bacteria, wherein the patient is hospitalized or will be hospitalized; or the patient will undergo surgery and/or be anesthetized, comprising administering to a patient an effective amount of a composition comprising a purified recombinant and attenuated Staphylococcus α-hemolysin (Hla) toxin, wherein the Hla toxin comprises no more than amino acids 1-50 of mature Hla toxin.

21. The method of claim 20 , wherein the patient has a staphylococcal lung disease or condition.

22. The method of claim 21 , wherein the staphylococcal lung disease or condition is pneumonia.

23. The method of claim 10 , wherein the staphylococcal lung disease or condition is pneumonia.

Assignments (2)
CONFIRMATORY LICENSE Recorded Nov 8, 2011
From: UNIVERSITY OF CHICAGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 027192/0276 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2010
From: BUBECK-WARDENBURG, JULIANE; SCHNEEWIND, OLAF; RAGLE, BROOK
To: THE UNIVERSITY OF CHICAGO
Reel/Frame 024569/0056 →
Continuity (2)
Provisional Application 60969514 · Aug 31, 2007
Related Publication 20110027265A1 · Feb 3, 2011